Is Jardiance a GLP-1?

Summary: Jardiance is empagliflozin, an SGLT2 inhibitor that makes the kidneys excrete glucose in urine. GLP-1 drugs are gut hormone analogs that work on appetite and insulin. The two classes are routinely confused, but they are not interchangeable, especially for weight loss.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: no. Jardiance is empagliflozin, an SGLT2 inhibitor. It is not a GLP-1 receptor agonist, it is not a cousin of Ozempic, and it does not work by the same mechanism. The two classes share a few headlines (both treat type 2 diabetes, both lower cardiovascular risk, both produce some weight loss) and that overlap is what makes people think they are related. They are not.

This page lays out what Jardiance actually is, what GLP-1 drugs actually are, why the two get mixed up, and what the head-to-head data look like for weight loss, A1C, and outcomes. If you are picking between them or stacking them, the differences matter.

What Jardiance is

Jardiance is the brand name for empagliflozin, marketed by Boehringer Ingelheim and Eli Lilly. It is a once-daily oral tablet at 10 mg or 25 mg ^[1]. It belongs to the class called SGLT2 inhibitors, sodium-glucose cotransporter-2 inhibitors. Other drugs in the same class include Farxiga (dapagliflozin), Invokana (canagliflozin), and Steglatro (ertugliflozin).

The mechanism is mechanical, not hormonal. SGLT2 is a protein in the proximal tubule of the kidney that reabsorbs glucose from the filtered urine back into the bloodstream. Block that protein and the glucose stays in the urine and gets peed out. People on Jardiance excrete roughly 60 to 80 grams of glucose per day in their urine, which is about 240 to 320 calories. That is where the modest weight loss comes from. It is not appetite suppression. It is glucose dumping.

The FDA-approved indications for Jardiance are type 2 diabetes (to improve glycemic control), reduction of cardiovascular death in adults with type 2 diabetes plus established cardiovascular disease, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease in adults ^[1]. That last group of indications is what gives Jardiance its real value. It is a cardio-renal protective drug that happens to also lower blood sugar.

What GLP-1 drugs are

GLP-1 stands for glucagon-like peptide-1. It is a peptide hormone your gut releases after a meal. Its job is to tell the pancreas to release insulin, tell the liver to stop dumping glucose, slow gastric emptying so food sits in the stomach longer, and signal the brain that you are full. The hormone is broken down within minutes by the enzyme DPP-4, which is why native GLP-1 has no practical drug value.

GLP-1 receptor agonists are synthetic peptides engineered to bind the same receptor but resist DPP-4 breakdown. The class includes semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist, technically a separate subclass but usually grouped with GLP-1s in clinical conversation.

The mechanism is hormonal. GLP-1 drugs do not touch the kidney. They work centrally in the brain (appetite) and peripherally in the pancreas (insulin) and gut (gastric emptying). The result is a much larger effect on body weight than anything SGLT2 inhibitors can produce.

One myth worth clearing up because it shows up in the secondary keyword list. GLP-1 drugs are not made from venom. The story comes from exendin-4, a peptide discovered in the saliva of the Gila monster lizard in the 1990s, which happens to have GLP-1-like activity and resists DPP-4 degradation. That research inspired exenatide (Byetta), the first GLP-1 receptor agonist approved in 2005. Modern GLP-1s like semaglutide and tirzepatide are not derived from venom or saliva. They are synthetic peptides designed from human GLP-1 sequences with engineered substitutions for stability and half-life. The Gila monster connection is historical, not chemical.

Side-by-side: Jardiance vs GLP-1 drugs

That last column tells you why the two classes get prescribed for very different patient profiles.

Why the two get confused

Three reasons. First, both treat type 2 diabetes, so they show up in the same Standards of Care guidelines and the same patient conversations. The American Diabetes Association recommends SGLT2 inhibitors and GLP-1 receptor agonists as preferred second-line options after metformin, often in the same paragraph ^[5]. Patients reasonably assume drugs in the same paragraph are the same class.

Second, both produce some weight loss, and both got a marketing halo from Ozempic mania. Telehealth ads frequently lump them together as "metabolic health" drugs without spelling out the mechanism. The headline number ("loses weight, lowers sugar") is similar enough at a glance that people assume the drug class is similar too.

Third, both reduce cardiovascular events, which is rare. Most diabetes drugs only lower blood sugar. The fact that Jardiance and Ozempic both showed mortality benefit in landmark trials (EMPA-REG OUTCOME for empagliflozin, SUSTAIN-6 for semaglutide) put them in the same elite tier in cardiology. That co-prominence makes them look interchangeable when they are not.

Weight loss: not the same league

This is the biggest practical difference. Jardiance produces real but modest weight loss. The EMPA-REG OUTCOME trial reported mean weight loss of about 2 kg (4.4 lb) over a median 3.1 years compared to placebo ^[2]. Real-world data tracks the same range, typically 3 to 5 lb at one year.

GLP-1 drugs at therapeutic doses produce 10 to 20% body weight loss. In the STEP 1 trial, weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body weight reduction at 68 weeks, versus 2.4% with placebo ^[4]. Tirzepatide in SURMOUNT-1 hit 20.9% at the 15 mg dose. For a 220 lb adult, that is the difference between losing 7 lb on Jardiance and losing 45 lb on Zepbound.

If your primary goal is weight loss, Jardiance is not the drug. It can contribute as part of a stack, and the weight that comes off tends to be sustained, but the magnitude is not comparable. Doctors who prescribe Jardiance for weight loss alone are doing it because the patient has another reason (heart failure, CKD) that justifies the drug, with weight loss as a bonus.

Cardiovascular and kidney data

The EMPA-REG OUTCOME trial randomized 7,020 adults with type 2 diabetes plus established cardiovascular disease to empagliflozin or placebo on top of standard care. Empagliflozin reduced the primary composite of CV death, nonfatal MI, or nonfatal stroke by 14%, and reduced CV death alone by 38% ^[2]. That was the first time an oral diabetes drug had ever shown a mortality benefit. It changed cardiology.

The EMPEROR-Reduced and EMPEROR-Preserved trials extended Jardiance into heart failure regardless of diabetes status. EMPEROR-Reduced (heart failure with reduced ejection fraction) showed a 25% reduction in CV death or hospitalization for heart failure ^[3]. EMPEROR-Preserved (preserved ejection fraction) showed a 21% reduction in the same composite, the first drug to ever show benefit in HFpEF. Those trials are why heart failure cardiologists prescribe Jardiance to patients who do not have diabetes at all.

GLP-1 drugs have their own CV outcomes data (SUSTAIN-6 for semaglutide, LEADER for liraglutide, REWIND for dulaglutide) showing MACE reduction. The mechanism is thought to be partly direct (vascular effects) and partly indirect (weight loss, glycemic control, blood pressure). The heart failure data for GLP-1s are less compelling than for SGLT2 inhibitors. If a patient has heart failure as the dominant comorbidity, SGLT2 wins. If obesity is dominant, GLP-1 wins.

When to use each

This is not a substitute for an endocrinologist's judgment. It is the rough shape of how these drugs get prescribed in practice. Many patients end up on both.

Can you combine Jardiance with a GLP-1?

Yes, and it is increasingly common in type 2 diabetes care. The two drugs work by completely different mechanisms, so the effects are additive. Combination therapy gets a patient A1C reductions in the 2.5 to 3.0% range, weight loss in the 15 to 20% range, plus the cardio-renal protection of SGLT2 plus the appetite control of GLP-1. The 2024 ADA Standards of Care explicitly endorse combination SGLT2 plus GLP-1 in patients with high cardiovascular or renal risk ^[5].

Side effects do not stack the way mechanisms do. GLP-1 side effects (nausea, GI) and SGLT2 side effects (UTIs, dehydration) are unrelated, so each appears at roughly its own baseline rate when combined. The one risk worth watching is volume status. SGLT2 inhibitors cause mild diuresis, and GLP-1s reduce fluid intake during the early nausea phase. Patients starting both drugs at once can get dehydrated faster than expected.

Where other diabetes drugs fit

A few of the secondary questions on this topic deserve quick answers since people confuse multiple drugs with GLP-1s, not just Jardiance.

Metformin is not a GLP-1. Metformin is a biguanide. It works mainly by reducing hepatic glucose production and improving insulin sensitivity. Some research suggests metformin may modestly increase endogenous GLP-1 levels as a secondary effect, but it is not an incretin mimetic and does not bind the GLP-1 receptor. It is not classified as an incretin.

Phentermine is not a GLP-1. Phentermine is a sympathomimetic amine, a stimulant in the same family as amphetamines. It suppresses appetite by raising norepinephrine in the brain. Different mechanism, different side effect profile (insomnia, raised blood pressure, raised heart rate), and approved only for short-term obesity treatment (typically 12 weeks).

Tresiba is not a GLP-1. Tresiba is insulin degludec, an ultra-long-acting basal insulin. It is exogenous insulin, not a hormone that triggers insulin release. Long-acting basal insulins and GLP-1s are often combined (Xultophy is a fixed-dose combo of degludec and liraglutide), but they are entirely separate drug classes.

Sitagliptin (Januvia) is related to GLP-1 but is not a GLP-1. Sitagliptin is a DPP-4 inhibitor. DPP-4 is the enzyme that breaks down native GLP-1. Blocking the enzyme raises endogenous GLP-1 levels modestly, but the effect is much weaker than a GLP-1 receptor agonist. DPP-4 inhibitors produce smaller A1C drops (~0.5 to 0.7%) and are weight neutral.

Nateglinide and tolbutamide are not GLP-1s. Nateglinide is a meglitinide and tolbutamide is a sulfonylurea. Both work by directly stimulating the pancreatic beta cell to release insulin regardless of glucose levels. They do not affect incretin duration of action.

Common questions about Jardiance and GLP-1s

Is Jardiance a GLP-1 receptor agonist?

No. Jardiance is empagliflozin, an SGLT2 inhibitor. It blocks glucose reabsorption in the kidneys. GLP-1 receptor agonists like Ozempic and Wegovy work on a completely different pathway, mimicking the gut hormone GLP-1.

Is Jardiance the same as Ozempic?

No. Ozempic is semaglutide, a weekly injectable GLP-1 agonist. Jardiance is empagliflozin, a daily oral SGLT2 inhibitor. Different class, different mechanism, very different weight loss magnitude.

Is Jardiance used for weight loss?

It produces modest weight loss (about 4 to 7 lb on average) as a side effect of dumping glucose in urine. The FDA has not approved Jardiance for obesity. GLP-1 drugs produce 10 to 20% body weight loss and are approved for that indication.

Can I take Jardiance and Ozempic together?

Yes, the combination is common in type 2 diabetes. The mechanisms are independent, so the effects on A1C and cardiovascular risk are additive. Both should be coordinated by your prescriber to monitor hydration and kidney function.

Is metformin a GLP-1?

No. Metformin is a biguanide. It reduces hepatic glucose production and improves insulin sensitivity. It may modestly raise endogenous GLP-1 as a secondary effect but is not classified as an incretin or a GLP-1 agonist.

Is phentermine a GLP-1?

No. Phentermine is a stimulant appetite suppressant in the amphetamine family. It works on norepinephrine in the brain, not on gut hormones. It is approved only for short-term weight loss, typically up to 12 weeks.

Is Tresiba a GLP-1?

No. Tresiba is insulin degludec, an ultra-long-acting basal insulin. It is exogenous insulin replacement, not a hormone analog that triggers insulin release.

Are GLP-1 drugs made from Gila monster venom?

No. The first GLP-1 drug, exenatide, was inspired by exendin-4, a peptide in Gila monster saliva discovered in the 1990s. Modern GLP-1s like semaglutide and tirzepatide are synthetic peptides designed from human GLP-1 sequences, not from any animal venom.

Does sitagliptin act like a GLP-1?

Sitagliptin (Januvia) is a DPP-4 inhibitor. It blocks the enzyme that breaks down native GLP-1, raising endogenous levels modestly. The effect is weaker than a GLP-1 receptor agonist and weight neutral, not weight-reducing.

What is the difference between incretin mimetics and sulfonylureas?

Incretin mimetics (GLP-1 agonists) signal the pancreas to release insulin only when glucose is high, and slow gastric emptying. Sulfonylureas force insulin release regardless of glucose level, which is why they cause hypoglycemia and modest weight gain. The two classes are mechanistically opposite in some ways.

Are there oral GLP-1 options?

Yes. Rybelsus is oral semaglutide, taken as a daily tablet. In the UK and EU, oral semaglutide is approved for type 2 diabetes. Most other GLP-1s remain injectable. Oral options are limited because peptides degrade in the stomach.

The bottom line

Jardiance is an SGLT2 inhibitor, not a GLP-1. The classes overlap on diabetes and cardiovascular benefit, which is why people confuse them, but the mechanism, the weight loss magnitude, the route of administration, and the side effect profile are all different. If you want a drug that produces 15% body weight loss, you want a GLP-1 (or tirzepatide). If you want a drug that reduces heart failure hospitalization or slows kidney decline in CKD, you want an SGLT2 inhibitor. Many patients with type 2 diabetes end up on both, and that combination is now considered best-practice care for high-risk patients.